Finance

Beta
Lists
688247:SHA
Sinotherapeutics Inc
CN¥8.52
-1.16%
(-0.100) 1D
May 29, 3:00:02 PM GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 688247...
Open
CN¥8.58
High
CN¥8.67
Low
CN¥8.43
Mkt. cap
3.91B
Avg. vol.
2.14M
Volume
1.86M
P/E ratio
97.11
52-wk high
CN¥13.28
52-wk low
CN¥8.36
EPS
CN¥0.09
No. of employees
319
Open
CN¥8.58
High
CN¥8.67
Low
CN¥8.43
Mkt. cap
3.91B
Avg. vol.
2.14M
Volume
1.86M
P/E ratio
97.11
52-wk high
CN¥13.28
52-wk low
CN¥8.36
EPS
CN¥0.09
No. of employees
319
News stories
From sources across the web
About Sinotherapeutics Inc
CEO-
Employees319
Founded2012
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in CNY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CNY
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
110.68M
111.86M
115.10M
94.55M
Cost of goods sold
64.64M
66.11M
74.36M
57.70M
Cost of revenue
64.64M
66.11M
74.36M
57.70M
Research and development expenses
13.25M
17.19M
32.05M
11.97M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
12.26M
13.51M
10.43M
10.59M
Operating expense
27.10M
27.57M
38.76M
22.54M
Total operating expenses
91.73M
93.67M
113.12M
80.24M
Operating income
18.95M
18.18M
1.98M
14.31M
Other non operating income
50.74K
-1.63M
-229.47K
3.68M
EBT including unusual items
27.75M
18.27M
-15.96M
18.38M
EBT excluding unusual items
25.76M
20.79M
-899.93K
18.61M
Income tax expense
2.65M
395.05K
17.31K
1.81M
Effective tax rate
9.56%
2.16%
-0.11%
9.86%
Other operating expenses
1.23M
-3.31M
-5.24M
-25.68K
Net income
25.10M
17.88M
-15.98M
16.56M
Net profit margin
22.67%
15.98%
-13.88%
17.52%
Earnings per share
-
-
-
-
Interest and investment income
7.09M
3.90M
1.13K
617.18K
Interest expense
-488.00
-480.00
-2.65M
-
Net interest expenses
7.09M
3.90M
-2.65M
617.18K
Depreciation and amortization charges
-
-
-
-
EBITDA
24.56M
22.76M
9.94M
22.27M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more

Research

AI content may include mistakes. Learn more